Brief: Synact Pharma Receives Favorable Us Patent Decision For Immediate-Release Resomelagon Tablet Formulation
05/08/2026 14:33
BRIEF-Synact Pharma Receives Favorable Us Patent Decision For Immediate-Release Resomelagon Tablet Formulation Aug 5 (Reuters) - SynAct Pharma AB SYNACT.ST:
RECEIVES FAVORABLE US PATENT DECISION FOR IMMEDIATE-RELEASE RESOMELAGON TABLET FORMULATION
Source text: ID:nMFNmJnvH
Further company coverage: SYNACT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on SynAct Pharma AB
See all newsSweden's SynAct Pharma Q3 net loss narrows as expenses fall
Brief: SynAct Pharma Q3 Net Income SEK -32.177 Million
Brief: SynAct Pharma Signs First Commercial Partnership For Resomelagon
Brief: WHO Names Resomelagon Among Key Dengue Drug Candidates
Brief: SynAct Pharma Says Advance Analysis Supports Phase 3 Development